{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274235","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.384744+00:00","generated_at":"2026-05-16T22:19:33.235918+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Assembly Biosciences Q3 net loss $9.2M; cash $232.6M; positive Phase 1b data for ABI-5366","bullets":["Net loss of $9.2M ($0.72 per share) vs $9.6M loss in Q3 2024; revenue from Gilead collaboration $10.8M.","Cash, cash equivalents and marketable securities $232.6M as of Sep 30, 2025; projected to fund operations into late 2027.","Raised $175M gross proceeds from equity financing with institutional investors in August 2025.","Positive Phase 1b interim data for ABI-5366: significant reductions in HSV-2 shedding and genital lesion rates in recurrent genital herpes.","Phase 1a interim data for ABI-6250 supports progression to Phase 2; additional HSV data (ABI-5366, ABI-1179) expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274235","json":"https://secwatch.observer/filing/0001193125-25-274235.json","markdown":"https://secwatch.observer/filing/0001193125-25-274235.md","text":"https://secwatch.observer/filing/0001193125-25-274235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000119312525274235/0001193125-25-274235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000119312525274235/asmb-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:19:33.235918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}